Studies have shown that active fund managers routinely underperform the S&P500 index*​

Atara Biotherapeutics, Inc. (NASDAQ: ATRA)

ATRA Stock Predictions and Ratings

WSX Rating:
BUY
WSX Forecast (1yr):
253.30%
Analyst Rating:
BUY
Analyst Forecast (1yr):
-40.30%

ATRA Stock Analysis

ATRA PE Ratio:

ATRA PEG Ratio: Not Available

ATRA Forward EPS Growth (12 month): 0.00%

ATRA PS Ratio: 3.7

ATRA PSG Ratio:

ATRA Forward Revenue Growth (12 month): 260.40%

ATRA Articles

No data was found